Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood GLP1, Blood No treated GLP1.
- Who it may be relevant to
- Registry conditions: Obesity. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.
Interventions
- Other Blood GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues - Other Blood No treated GLP1
On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
Primary outcome measures
- Rate of oxytocin [Time frame: one time (before surgery)]
Secondary outcome measures (1)
- Fibrosis rate [Time frame: At surgery]
Eligibility criteria
Inclusion criteria
- Patient over 18 years of age.
- Patient able to read and understand the information/consent leaflet.
- Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
- Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
- Membership of a social security scheme
- Patient's signed informed consent
- For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
- For non-GLP-1 analogue group: never taken GLP-1 analogues.
Exclusion criteria
- Pregnant or breast-feeding women.
- Vulnerable patients (under guardianship)
- Patients deprived of liberty
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- CHU de Nice - Hôpital de l'Archet — Nice
Identifiers
NCT: NCT06278285 · 21-AOIP-01